Inhibition of Amyloid Formation

Sammanfattning

Amyloid is aggregated protein in the form of insoluble fibrils. Amyloid deposition in human tissue-amyloidosis-is associated with a number of diseases including all common dementias and type II diabetes. Considerable progress has been made to understand the mechanisms leading to amyloid formation. It is, however, not yet clear by which mechanisms amyloid and protein aggregates formed on the path to amyloid are cytotoxic. Strategies to prevent protein aggregation and amyloid formation are nevertheless, in many cases, promising and even successful. This review covers research on intervention of amyloidosis and highlights several examples of how inhibition of protein aggregation and amyloid formation has been achieved in practice. For instance, rational design can provide drugs that stabilize a native folded state of a protein, protein engineering can provide new binding proteins that sequester monomeric peptides from aggregation, small molecules and peptides can be designed to block aggregation or direct it into non-cytotoxic paths, and monoclonal antibodies have been developed for therapies towards neurodegenerative diseases based on inhibition of amyloid formation and clearance. (c) 2012 Elsevier Ltd. All rights reserved.

Nyckelord

protein aggregation; amyloidosis; drug discovery; protein engineering; neurodegenerative disease

Publicerad i

Journal of Molecular Biology
2012, volym: 421, nummer: 4-5, sidor: 441-465
Utgivare: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

SLU författare

• Härd, Torleif

  • Institutionen för molekylärbiologi, Sveriges lantbruksuniversitet
    

• Lendel, Christofer

  • Institutionen för molekylärbiologi, Sveriges lantbruksuniversitet
    

Globala målen (SDG)

SDG3 God hälsa och välbefinnande

UKÄ forskningsämne

Läkemedelsbioteknik
Medicinsk bioteknik
Biokemi och molekylärbiologi

Publikationens identifierare

• DOI: https://doi.org/10.1016/j.jmb.2011.12.062

Permanent länk till denna sida (URI)

https://res.slu.se/id/publ/40818